2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
3
Active Trials
200 recruiting
7
Rare Diseases
across 13 areas
0
News (30d)
Quiet
Dren Bio, Inc is a company with 2 orphan drug designations across 7 rare diseases. Active clinical trials in 3 indications.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| T-cell large granular lymphocyte leukemia | human anti-CD94 IgG1 monoclonal antibody (non-fucosylated) | Des.TrialAppr. |
| T-cell non-Hodgkin lymphoma | human anti-CD94 IgG1 monoclonal antibody (non-fucosylated) | Des.TrialAppr. |
| aggressive NK-cell leukemia | human anti-CD94 IgG1 monoclonal antibody (non-fucosylated) | Des.TrialAppr. |
| chronic lymphoproliferative disorder of NK-cells | human anti-CD94 IgG1 monoclonal antibody (non-fucosylated) | Des.TrialAppr. |
| lupus erythematosus | - | Des.TrialAppr. |
| ovarian cancer | - | Des.TrialAppr. |
| vitiligo | - | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
24
overlap in 2+ diseases
0/7
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
24
overlap in 2+ diseases
0/7
candidate diseases
0
avg importance: 0
0
affecting portfolio